Antitumor effect of endothelial monocyte-activating polypeptide-ii on human prostateadenocarcinoma in mouse xenograft model
Summary. Endothelial monocyte-activating polypeptide-II (EMAP-II) is a novel proinflammatory cytokine with anti-angiogenic properties. The aim of this work was to evaluate in vivo antitumor activity of EMAP-II in growing human prostate adenocarcinoma xenograft mouse model. Materials and Methods: Recombinant human EMAP-II was expressed in Escherichia coli and purified after cleavage with enterokinase (EMAP-IIe). EMAP-II preparations were injected to CBA mice bearing subrenal capsule xenografts of human prostate adenocarcinoma. After 3-days treatment, the xenografts were isolated and weighed, then the transplants exposed to EMAP IIe (100 or 200 µg/kg b. w.) were examined histologically. Results: EMAP-II administered daily at a dose of 100 or 200 µg/kg b. w. caused striking retardation of local tumor progression as compared to the controls. Low dose (10 µg/kg) was effective in some cases. Conclusion: EMAP II exhibits significant antitumor activity in vivo in human prostate adenocarcinoma xenografts in mouse model.
No Comments » Add comments